Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio Prof\textsuperscript{1,2,*}, Omid Hamid MD\textsuperscript{3}, James Larkin MD PhD\textsuperscript{4}, Alessia Covre PhD\textsuperscript{1}, Maresa Altomonte MD\textsuperscript{1}, Luana Calabrò MD\textsuperscript{1}, Santosh A. Vardhana MD\textsuperscript{5}, Caroline Robert MD PhD\textsuperscript{6}, Ramy Ibrahim MD\textsuperscript{7}, Andrea Anichini PhD\textsuperscript{8}, Jedd D. Wolchok MD PhD\textsuperscript{5}, Anna Maria Di Giacomo MD\textsuperscript{1}

\textsuperscript{1}Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy; \textsuperscript{2}NIBIT Foundation Onlus, Italy; \textsuperscript{3}The Angeles Clinic and Research Institute, Los Angeles, California, USA; \textsuperscript{4}The Royal Marsden Hospital, London, UK; \textsuperscript{5}Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA; \textsuperscript{6}Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France; \textsuperscript{7}Parker Institute For Cancer Immunotherapy, San Francisco, California, USA; \textsuperscript{8}Human Tumor Immunobiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.

Running Title: Check-point inhibitors and COVID-19

Keywords: Check-point inhibitors, COVID-19, cancer, immunotherapy

Additional information:
• **Financial support:** This work was supported in part by funding from the FONDAZIONE AIRC under 5 per Mille 2018 – ID 21073 program (principal investigator M. Maio)

• **Address for correspondence:** Prof Michele Maio, MD
  
  Center for Immuno-Oncology
  Medical Oncology and Immunotherapy
  University Hospital of Siena
  Viale Mario Bracci, 16
  Siena, 53100 – Italy
  Phone: +390577586336
  mmaiocro@gmail.com

• **Conflicts of interest:** MM has served as a consultant and/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, Astra Zeneca, Glaxo Smith Kline, and Merck Serono. OH has served as consultant and/or advisor to Amgen, Novartis, Roche, Bristol-Myers Squibb, Merck, Aduro, Akeso Biopharma, Array BioPharma, BeiGene, Genentech, GSK, Immunocore, Incyte, Janssen, NextCure, Regeneron, Sanofi, Seattle Genetics, Tempus, Xelluna; he has received honoraria from Bristol-Myers Squibb, Novartis, Array BioPharma, Sanofi/Regeneron; he has received research funding from AZ, Bristol-Myers Squibb, Genentech, Immunocore, Roche, Amgen, MedImmune, Pfizer, CytomX Therapeutics, Iovance Biotherapeutics, NextCure, GSK, Arcus Bioscience, Aduro Biotech, Sanofi, Regeneron, Moderna Therapeutics, Array BioPharma, Akeso Biopharma, Seattle Genetics, Torque, Zelluna. JL has served as consultant to
Achilles, AZ, Boston Biomedical, BMS, Eisai, EUSA Pharma, GSK, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, MSD, Nektar, Novartis, Pierre Fabre, Pfizer, Roche/Genentech, Secarna, Vitaccess; has received Institutional research support from BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, Aveo; has received support from NIHR RM/ICR Biomedical Research Centre for cancer. LC has served as consultant and/or advisor to Bristol-Myers Squibb and Merck Sharp Dohme. SAV has served as a consultant and/or advisor to ADC therapeutics and Immunai. CR receiving personal fees from Merck Sharpe & Dohme, Amgen, Bristol-Myers Squibb, Novartis, Pierre Fabre, Roche, Sanofi. RI has served as Board of Director to Surface Oncology; has served as Observer Board of Director to Lyell; has served as Scientific Advisor to Arcus, Harpoon, BitBio, ImaginAb. JDW has served as a consultant to Adaptive Biotech, Amgen; Apricity, Ascentage Pharma, Astellas, AstraZeneca; Baye, Beigene, Bristol Myers Squib, Celgene, Chugai, Eli Lilly, Elucida; F Star, Imvaq, Janssen, Kyowa Hakko Kirin, Linneaus, Merck, Neon Therapuetics, Novartis, Polynoma, Psioxu, Recepta, Takara Bio, Trieza, Truvax, Serametrix, Surface Oncology, Syndax, Syntalogic; he received research support from Bristol Myers Squibb, AstraZeneca, Sephora; he has equity in Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus. AMDG has served as a consultant and/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline and Bristol-Myers Squibb. AC and MA declare no conflicts of interest.

- Word count: 2052
**Total number of figures and tables: 3 (2 figures and 1 table)**

**Translational relevance**

Infection by the Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) poses major challenges to cancer patients and treating physicians due to the potential cross-interference of COVID-19 disease and cancer treatment with immune-checkpoint inhibitors (ICI). In this specific context literature is very limited, though available evidence can still help shedding some light on the potential intersection between ICI therapy and SARS-CoV-2 infection. However, since the COVID-19 pandemic will likely represent a major concern also for the future, significant clinical and translational issues and questions will need to be addressed. Therefore, it seems useful to provide some practical guidance for today and to highlight research paths for the future.
Abstract

The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to consider, checkpoint inhibitors (ICI) seem to require major attention as they may act at the cross-road between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. Based on available literature evidences, we suggest guidance to consider for treating physicians, and propose areas of clinical and pre-clinical investigation. Comprehensively, though with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for cancer patients during the COVID-19 pandemic.
Introduction

During this challenging period of the coronavirus (COVID-19) pandemic, the scientific community and cancer patients are thoughtfully considering the possible interference of cancer treatment on the clinical course of COVID-19 infection. Amid different therapeutic strategies available in the clinic, chemotherapy, target therapy and/or radiotherapy may play a possible role; however, major concerns are raised by immunomodulatory drugs, due to their intrinsic and pleiotropic effect on the functional activity of patients' immune system. Among those, being immune-checkpoint inhibitors (ICI) the pillar of cancer immunotherapy in different solid tumor types world-wide, they undoubtedly represent the focus of greatest attention for their potential intersection with COVID-19 infection (Table 1). Unfortunately, though, no compelling scientific evidence is available yet to confirm or deny this potential relationship. Nevertheless, COVID-19 disease represents a major clinical threat for cancer patients today, and will likely be such in the next months, if not years; therefore, some sort of guidance/recommendations are needed nowadays and prospectively, when ICI therapy represents the treatment of choice for a given cancer patient. In this complex and dynamic clinical scenario, in spite of the paucity of scientific data, available literature evidence may help to identify a practical therapeutic algorithm for ICI therapy of cancer patients that can currently provide guidance to treating physicians. However, efforts will be clearly required to identify pre-clinical and clinical gaps and questions that need to be filled and addressed, to further unveil the potential interference of ICI therapy on COVID-19 disease in cancer patients.
Where we stand

First, the Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2), the agent responsible for COVID-19, is a newly identified strain of the single-stranded RNA coronavirus (CoV) family including the Severe Acute Respiratory Syndrome (SARS-CoV) and the Middle East Respiratory Syndrome (MERS-CoV), that generated the 2002 and 2012 epidemics, respectively (1). All three strains are known to cause severe, and even fatal, lower respiratory infections. A common laboratory hallmark of these infections has been circulating lymphopenia, and SARS-CoV and MERS-CoV have specifically been shown to deplete CD4+ T cells and induce T cell apoptosis (2). In accordance with this finding, lymphopenia in SARS-CoV-2-infected patients worsens as patients clinically deteriorate and recovers as patients improve (2). Furthermore, in the early phase of COVID-19 infection circulating T-cells can express surface molecules consistent with early activation (i.e., CD38, HLA-DR) (3), and upregulate PD-1 (2). This increase in PD-1 expression may represent a marker of T-cell exhaustion on one side, though it is also consistent with phenotypic changes associated with the early phases of T cell priming in the context of acute viral infections (4). As far as ICI, therapeutic targeting of CTLA-4 swiftly expands the CD4+ and CD8+ pool of T cells, while therapeutic PD-1/PD-L1 engagement re-invigorates exhausted T cells (5). Altogether, these findings seem to support the possibility that ICI treatment may contribute to counteract the immunologic impairment of T cell number and function induced by COVID-19 infection. Thus, in one potential mechanistic scenario ICI treatment may ameliorate the early phase of COVID-19 disease by contributing to viral clearance also
through the re-activation of PD-1+ viral epitope-specific T cells (Fig. 1a). On the other hand, ICI therapy may instead tilt the immunological balance favoring COVID-19 disease worsening towards its more aggressive inflammatory late stage through the promotion of different immune-activating mechanisms (Fig. 1a).

A second piece of evidence derives from a large number of clinical trials in which patients with solid and hematopoietic malignancies of different histologic types, and with a concomitant HIV, HBV and/or HCV infection, were treated with ICI. Remarkably, toxicity and efficacy rates were reported to be similar to those observed in patients without viral infection, and viral reactivation was not observed (6,7). Of note, similar results were observed in patients with advanced hepatocellular carcinoma with HCV or HBV infection who were receiving anti-viral therapy (8). Based on these findings, ICI therapy was concluded to be safe and effective in patients with virally-related or -unrelated malignancies (6-8). Notably, alike SARS-CoV-2, HIV and HCV are RNA viruses (9).

A third piece of evidence concerns the potential contribution of ICI therapy on the systemic inflammatory response to SARS-CoV-2-associated pathology that characterizes the late stage of the disease. Indeed, higher levels of circulating IL-6, produced mainly by innate immune cells in response to virally-mediated Toll-like receptor activation, were identified in hospitalized subjects with a more severe COVID-19 disease course (10). Also ICI-therapy can be associated with increased cytokine-mediated toxicity (11); however, this does not seem to represent a significant clinical issue since in the late, inflammatory stage, of COVID-19 disease the therapeutic attention is fully paid on rescuing patients from the COVID-19 induced organ failures.
Conversely, ICI-mediated cytokine release may rather represent a clinical issue in the early phase of SARS-CoV-2 infection, as it may worsen the morbidity and clinical course of COVID-19 disease, as discussed above. Even in this potential occurrence, treatment with the anti-IL-6 tocilizumab may help as it has been reported to improve clinical symptoms related to COVID-19 disease (12).

Present and prospective challenges

The retrospective evidence above and the considerations one can draw at present, seem to comprehensively point to a modest interference of ICI therapy on COVID-19 course; however, in the absence of robust clinical and laboratory data, caution must be taken in transposing these concepts “tout court” to our daily practice during the time of the COVID-19 pandemic. Adding complexity to this scenario is the generally unknown COVID-19 infection status of cancer patients when initial therapeutic decisions are made or, even more challenging, when ICI therapy is ongoing (Fig. 2).

One could argue that in order to be on the safer-side, chemotherapy could represent an alternative to ICI treatment. However, this quite “conservative” approach should be carefully balanced against the clinical benefit of chemotherapy compared to ICI, and towards its generally immunosuppressive activity that can be worsened when associated with radiotherapy. Furthermore, when target therapy can represent a valid alternative to ICI treatment it could be a strategy to be pursued, though a limited percent of cancer patients is suitable to targeted agents. The possible interference of these diverse therapeutic strategies in facilitating COVID-19 infection, or in worsening the course of disease in asymptomatic subjects who are unknown to be COVID-19 positive.
remains to be fully unveiled. Answer to these questions will hopefully derive in the next months from the ongoing collections of large series of prospective data.

It is undoubtful that ICI represent the ever-growing therapeutic strategy in different cancer types, in which they have received approval by regulatory Agencies world-wide (Table 1); these increasing clinical successes make ICI a field with the most investigated anti-cancer drugs, either alone or in novel combinations/sequences (13). Against this background, a further significant practical impact that COVID-19 pandemic is undoubtedly having in our referral Institutions, as well as in major Centers world-wide having a strong focus on clinical research, is the present pause of the very large majority of ongoing and novel ICI-based clinical trials. This adds up to the redirection, also at the expense of oncology, of health resources towards COVID-19 disease. As a comprehensive consequence, at the moment cancer patients cannot receive treatment with novel medicines and new therapeutic combinations that may give them more hope for cure or improved survival, as compared to standard therapies.

Thus, what can be suggested nowadays from a practical standpoint regarding ICI therapy and COVID-19 infection based on the available evidence?

From a clinical viewpoint, when ICI treatment represents the therapy of choice, it seems neither reasonable to deny it to cancer patients nor to interrupt its administration fearing COVID-19 infection. However, closer monitoring of ICI-treated patients should be strongly recommended due to the potential development of ICI-related pneumonitis, where treatment is definitively different as compared to COVID-19 infection (14). Individual discussions with patients weighing the risk and benefit of combination versus single agent ICI are critical given the more frequent need for immune suppression to
treat toxicity with combination therapy. Being elderly cancer patients at higher risk to develop severe COVID-19 disease, the decisions with ICI in combination should be much more judicious in this population. Further, the use of ICI in adjuvant settings, which already incorporates a challenging discussion of the possibility of long-term toxicity in potentially cured patients is now even more important. Additionally, screening for COVID-19 disease before ICI therapy is strongly recommended to minimize the risk of activating treatment in SARS-CoV-2 infected asymptomatic patients. Consistently, patients who develop symptoms that recall COVID-19 disease during ICI therapy should be swiftly screened for SARS-CoV-2 infection (Fig. 2). This strategy seems to become an increasingly feasible approach due to the availability of rapid molecular and serological mass screening tests, and to the growing perception by health providers that cancer is here to stay, even during the COVID-19 pandemic, and that significant resources cannot be diverted from cancer care (Fig. 2). Based on the considerations above, and from very initial observations reporting a positive outcome of COVID-19 disease in the course of ICI therapy (15), it seems reasonable to suggest/envisage a short-term therapeutic algorithm for ICI therapy during the COVID-19 pandemic, to help physicians in the decisions they are called to make every day (Fig. 2). However, it is imperative for the oncology community to collect prospective data on the COVID-19 status in as much as possible ICI-treated cancer patients, also because the pandemic will not be unfortunately over for the next months to come. This will allow to interrogate in-depth the clinical intersection between ICI therapy and SARS-CoV-2 infection, building a long-term therapeutic algorithm for cancer patients that will be most likely needed due to the forecasted persistence of COVID-19 disease world-wide (Fig. 2).
From a pre-clinical viewpoint it seems crucial that prospective studies are designed to unveil the potential intersection of ICI therapy and SARS-COV-2 infection in the early phase of COVID-19 disease, when ICI treatment represents an unquestionable and challenging need for cancer patients. These studies should be aimed at validating the retrospective evidence pointing to a modest interference of ICI therapy on the course of COVID-19 disease (Fig. 1a).

On the other hand, the possible effect of SARS-COV-2 infection on ICI-mediated anti-tumor immunity cannot be ruled out. Therefore, studies should also be designed to investigate the potential skewing effects of COVID-19 disease on all aspects of the cancer immunity cycle. This includes understanding how SARS-COV-2 infection impacts on the functional differentiation of circulating and tumor-associated T cells in cancer patients, on the structure of the tumor immune contexture, on the profile of crucial chemokines that recruit distinct immune cell subsets at tumor site, and on the spectrum of pro-inflammatory cytokines co-modulated by COVID-19 and ICI (Fig. 1b).

Conclusions

Though with the necessary caution, it seems reasonable to suggest that ICI therapy should not in principle be presently excluded as a therapeutic option of cancer patients in the COVID-19 era. Thoughtful discussions within the oncology community and with patients are anyway more important than ever. Filling clinical and pre-clinical gaps will be mandatory to provide strong evidence-based therapeutic guidance and mechanistic insights on the possible immune intersection between COVID-19 disease and cancer therapy.
Authors’ contribution

MM, AMDG conceived the study and wrote the original draft of the manuscript with contributions by JDW. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Acknowledgments

This work was supported in part by funding from the FONDAZIONE AIRC under 5 per Mille 2018 – ID 21073 program (principal investigator M. Maio)
References


8. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-


Figures Legend:

Fig. 1 Landscapes of potential intersection between ICI therapy and COVID-19 disease in cancer patients.

a, cancer immunotherapy by immune checkpoint inhibitors (ICI) in patients infected by SARS-COV-2 virus could potentially impact on clinical evolution of COVID-19 disease. In the instance of PD-1/PD-L1 axis blockade, PD-1\(^{+}\) viral epitope-specific T cells may be functionally reactivated and TNF-\(\alpha\) production by such T cells could be boosted. This may lead to two opposite consequences: promotion of Treg activation; exacerbation of cytokine storm, rather than increasing viral clearance and possibly inducing direct anti-viral effect by TNF-\(\alpha\). b, anti-tumor activity of ICI may be skewed in opposite directions by systemic immunological changes due to COVID-19: SARS-COV-2-induced lymphopenia and cytokine storm could negatively impact respectively on the magnitude of the peripheral pool of pre-exhausted tumor-specific T cells and compromise the function of tumor-specific T cells; however, opposite effects cannot be ruled out, such as enhanced migration of T cells to tissues that are at the same time sites of infection and of cancer growth (for example the lung in NSCLC patients treated with ICI) or TNF-\(\alpha\) mediated promotion of APC-T cross talk and T cell function.

Fig. 2 Present and prospective scenarios of ICI therapy in cancer patients during the COVID-19 era.
Table 1: Immunotherapeutic agents approved by FDA and EMA.

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>ICI</th>
<th>Other immunotherapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal cell carcinoma</td>
<td>PD1</td>
<td>Anti-TLR7</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>PD1, PD-L1</td>
<td>BCG</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>PD1</td>
<td>None</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>PD1, PD1+CTLA-4</td>
<td>None</td>
</tr>
<tr>
<td>Cutaneous squamous cell carcinoma</td>
<td>PD1</td>
<td>Anti-TLR3</td>
</tr>
<tr>
<td>Gastroesophageal cancer</td>
<td>PD1</td>
<td>None</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>PD1</td>
<td>None</td>
</tr>
<tr>
<td>Head and neck cancer</td>
<td>PD1, PD1+CHT</td>
<td>None</td>
</tr>
<tr>
<td>Melanoma</td>
<td>PD1, CTLA-4, PD1+CTLA-4</td>
<td>IL-2, IFN alfa-2b, T-VEC</td>
</tr>
<tr>
<td>Merkel cell carcinoma</td>
<td>PD1, PD-L1</td>
<td>None</td>
</tr>
<tr>
<td>MSI-H or dMMR cancer</td>
<td>PD1</td>
<td>None</td>
</tr>
<tr>
<td>Non small-cell lung cancer</td>
<td>PD1, PD-L1, PD1+CHT, PD-L1+CHT+anti-VEGF</td>
<td>None</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>PD1, PD1+CTLA-4, PD1/-L1+anti-VEGFR</td>
<td>IL-2</td>
</tr>
<tr>
<td>Small-cell lung cancer</td>
<td>PD1, PD-L1+CHT</td>
<td>None</td>
</tr>
<tr>
<td>Triple negative breast cancer</td>
<td>PD-L1+CHT</td>
<td>None</td>
</tr>
</tbody>
</table>

FDA, Food and Drug Administration; EMA, European Medicines Agency; ICI, immune-checkpoint inhibitors; PD1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TLR, Toll-like receptor; BCG, Bacillus Calmette-Guérin; CTLA-4, Cytotoxic T Lymphocyte Antigen-4; CHT, chemotherapy; IL-2, interleukin-2; IFN, Interferon; T-VEC, Talimogene laherparepvec; MSI-H, microsatellite instability-high; dMMR, mismatch repair-deficient; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Fig. 1
Short-term scenario
Due to redirection of health resources towards the COVID-19 pandemic

Long-term scenario
Due to restored health resources for oncology allowing mass screening for COVID-19 status

Fig. 2
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio, Omid Hamid, James Larkin, et al.